News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Manufacturing
Deals
Business
Job Trends
Cell and Gene Therapy
Cancer
Opinions
Press Releases
All News & Releases
Podcasts
Events
Jobs
Companies
Hotbeds
More
Reports
Career Advice
NextGen: Top Startups to Watch
40 Under 40
Best Places to Work
Employer Resources
Advertise
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Submit an Event
Search Query
Submit Search
News
Business
Active Biotech AB Interim Report Jan-Sep 2006
November 2, 2006
|
1 min read
Twitter
LinkedIn
Facebook
Email
Print
LUND, SWEDEN -- (MARKET WIRE) -- November 02, 2006 -- * Teva's Phase II study with laquinimod against MS successfully concluded
Twitter
LinkedIn
Facebook
Email
Print
Earnings
Europe
MORE ON THIS TOPIC
Earnings
Biogen’s ‘Bridge To Growth’ Cuts Through a Stacked Phase 3 Pipeline
February 6, 2026
·
2 min read
·
Annalee Armstrong
IPO
Eikon Clocks Largest IPO Since 2024, Generate, AgomAb Follow
February 6, 2026
·
5 min read
·
Tristan Manalac
Layoff Tracker
Charles River, Thermo Fisher Lay Off Staff Amid Site Closures
February 6, 2026
·
51 min read
·
BioSpace Editorial Staff
GLP-1
Makary Blasts ‘Illegal Copycat Drugs’ as Hims Launches Compounded Wegovy Pill
February 6, 2026
·
1 min read
·
Tristan Manalac
